---
figid: PMC9332003__ijms-23-08144-g003
pmcid: PMC9332003
image_filename: ijms-23-08144-g003.jpg
figure_link: /pmc/articles/PMC9332003/figure/ijms-23-08144-f003/
number: Figure 3
figure_title: ''
caption: EPO regulates neurotransmitter levels in the brain. The administration of
  rhEPO influences the concentrations of several neurotransmitters, such as (A,E)
  dopamine, (B,F) serotonin, (C,G) adrenaline, and (D,H) acetylcholine, in both hippocampus
  and cortex tissues. n = 4 per group. * p < 0.05, ** p < 0.01, *** p < 0.005, and
  **** p < 0.0001 according to independent t-test in (A–H).
article_title: Therapeutic Effect of Erythropoietin on Alzheimer’s Disease by Activating
  the Serotonin Pathway.
citation: Kyu-Ho Shim, et al. Int J Mol Sci. 2022 Aug;23(15):8144.
year: '2022'

doi: 10.3390/ijms23158144
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI

keywords:
- therapeutics
- erythropoietin
- serotonin
- Alzheimer’s disease
- amyloid beta-peptides
- cognitive dysfunction

---
